Goldman Sachs
ARTV

Goldman Sachs’s Artiva Biotherapeutics ARTV Stock Holding History

Goldman Sachs’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Buy
15,780
+4,315
+38% +$39.3K ﹤0.01% 6267
2026
Q1 		$73.8K Sell
11,465
-595
-5% -$2.94K ﹤0.01% 6247
2025
Q4 		$51.7K Sell
12,060
-37,717
-76% -$142K ﹤0.01% 6284
2025
Q3 		$143K Sell
49,777
-68,226
-58% -$183K ﹤0.01% 6014
2025
Q2 		$178K Buy
118,003
+76,051
+181% +$160K ﹤0.01% 5692
2025
Q1 		$126K Buy
41,952
+3,882
+10% +$21K ﹤0.01% 5740
2024
Q4 		$384K Buy
38,070
+8,523
+29% +$102K ﹤0.01% 5384
2024
Q3 		$457K Buy
+29,547
New +$342K ﹤0.01% 5098

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Goldman Sachs's ARTV Position: Q2 2026 in Review

Goldman Sachs increased its Artiva Biotherapeutics (ARTV) stake by 38% in Q2 2026, buying an estimated $39.3K and bringing the position to 15,780 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #6267.

Goldman Sachs first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $457K in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Goldman Sachs held 15,780 shares of Artiva Biotherapeutics worth $153K as of Q2 2026.
  • Goldman Sachs bought 4,315 Artiva Biotherapeutics shares in Q2 2026, an estimated $39.3K.
  • Artiva Biotherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6267 holding.
  • Goldman Sachs first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • Goldman Sachs's Artiva Biotherapeutics position peaked at $457K in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.